ChronTech Pharma AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
ChronTech Pharma AB Announces Results of New Studies on IVIN Technology
ChronTech Pharma AB announced that new studies have shown that the Company's IVIN technology is efficacious and that a better immune response is achievable using the same or even lower doses of DNA than when using a regular injection needle, irrespective of whether the injection is used in combination with in vivo electroporation or not. IVIN increases the number of vaccine specific T cells by more than 100% as compared to a regular needle when in combination with electroporation. Using IVIN strong immune responses can be achieved even when the dose is reduced 100-folds.
Latest Developments for ChronTech Pharma AB
- ChronTech Pharma's vaccine acts against liver cells that produce parts of HDV
- ChronTech Pharma AB Completes Sale of Hepatitis Technologies
- ChronTech Pharma AB Transfers 70% of Hepatitis B and C DNA Vaccines Project to Group of Shareholders
- ChronTech Pharma AB Announces Results from Controlled Clinical Study of ChronVac-C
- Share this
- Digg this